BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1247-1254

  Shim, Hyun Jeong ^a   Yun, Joo Young ^a   Hwang, Jun Eul ^a   Bae, Woo Kyun ^a   Cho, Sang Hee ^a   Lee, Ji Hee ^a   Kim, Hee Nam ^b   Shin, Min Ho ^a   Kweon, Sun Seog ^c   Lee, Jae Hyuk ^a   Kim, Hyeoung Joon ^b   Chung, Ik Joo ^d  

^a Chonnam National University Medical School   (South Korea)

^b Genome Research Centre for Hematopoietic Diseases   (South Korea)

^c Jeonnam Regional Cancer Center   (South Korea)

^d The Brain Korea 21 Project   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; PACLITAXEL; TAXANE DERIVATIVE; XRCC1 PROTEIN; XRCC3 PROTEIN; XRCC4 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; STOMACH SURGERY; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CISPLATIN; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS;

EID: 77953214042     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01514.x     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-50.
3. Shin HR, Jung KW, Won YJ. 2002 Annual Report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 2004, 36:103-14.
4. Murad AM, Santiago FF, Petroianu A. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72:37-41.
5. Pyrhonen S, Kuitunen T, Nyandoto P. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71:587-91.
6. Glimelius B, Ekstrom K, Hoffman K. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8:163-8.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24:4991-7.
8. Johnatty SE, Beesley J, Paul J. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008, 14:5-594.
9. Chang H, Rha SY, Jeung HC. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 2009, 20:272-7.
10. Goekkurt E, Hoehn S, Wolschke C. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006, 94:281-6.
11. Ruzzo A, Graziano F, Kawakami K. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006, 24:1883-91.
12. Weaver DA, Crawford EL, Warner KA. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005, 4:18.
13. Furuta T, Ueda T, Aune G. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62:4899-902.
14. Liu N, Lamerdin JE, Tebbs RS. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1998, 1:783-93.
15. Quinn JE, Carser JE, James CR. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009, 113:134-42.
16. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003, 63:6004-7.
17. Sohn KJ, Croxford R, Yates Z. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004, 96:134-44.
18. Morganti M, Ciantelli M, Giglioni B. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 2005, 41:2176-83.
19. Kim HN, Lee IK, Kim YK. Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. Br J Haematol 2008, 140:287-94.
20. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003, 111:1843-50.
21. Cheng XD, Lu WG, Ye F. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res 2009, 28:91.
22. Pacetti P, Giovannetti E, Mambrini A. Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine. Anticancer Res 2009, 29:1835-40.
23. Huang ZH, Hua D, Du X. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 2009, 64:1001-7.
24. Goekkurt E, Al-Batran SE, Hartmann JT. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 2009, 27:2863-73.
25. Liu B, Wei J, Zou Z. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 2007, 15:1049-53.
26. Kim K, Kang SB, Chung HH. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 2008, 111:509-15.
27. Gowen LC, Avrutskaya AV, Latour AM. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998, 281:1009-12.
28. Kennedy RD, Quinn JE, Mullan PB. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96:1659-68.
29. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2000, 2:483-90.
30. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25:5864-74.
31. Deng CX, Wang RH. Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet 2003, 12(Spec No 1):R113-23.
32. Quinn JE, Kennedy RD, Mullan PB. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63:6221-8.
33. Gilmore PM, McCabe N, Quinn JE. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res 2004, 64:4148-54.
34. Cass I, Baldwin RL, Varkey T. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97:2187-95.
35. Goffin JR, Chappuis PO, Begin LR. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003, 97:527-36.
36. Kim HP, Lee JE, Shin ES. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 2008, 26:5972-9.
37. Taron M, Rosell R, Felip E. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443-9.